Targeting PELP1 oncogenic signaling in TNBC with the small molecule inhibitor SMIP34.

Kristin A AltweggUday P PratapZexuan LiuJunhao LiuJohn R SanchezXue YangBehnam EbrahimiDurga Meenakshi PanneerdossXiaonan LiGangadhara R SareddySuryavathi ViswanadhapalliManjeet K RaoRatna K Vadlamudi

Published in: Breast cancer research and treatment (2023)

Together, these findings from in vitro, ex vivo, and in vivo models show that SMIP34 may be a useful therapeutic agent for inhibiting PELP1 signaling in TNBC.

Keyphrases

small molecule
signaling pathway
transcription factor
protein protein